A recent trial conducted by researchers from the University of Oxford and Kings College London found that a higher dose of the antibody injection benralizumab could be more effective in managing asthma and COPD flare-ups than standard steroid tablets. This could be a game-changer for the millions of people struggling with these conditions, as it could reduce the need for further treatments by 30%. The study showed that benralizumab improved respiratory symptoms and quality of life for participants, indicating promising potential for treating asthma and COPD. Researchers hope to provide life-saving options for patients with these conditions, which have not seen significant advancements in treatment for decades.
Source link
Single Dose Of Existing Antibody Injection May Cut Hospitalizations
